Orally Assimilable Or Injectable Composition Patents (Class 424/643)
  • Patent number: 10517322
    Abstract: Provided herein are formulations and methods helping individuals enhance cognitive function, facilitate memory processing, induce and maintain sleep, stabilize mood, reduce symptoms of stress and anxiety, facilitate energy production, improve mental and emotional health, or support long-term brain health.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: December 31, 2019
    Assignee: Life Kitchen, LLC
    Inventor: James Wukjae Lee
  • Patent number: 10376601
    Abstract: An in-vivo intravascular blood replacing liquid of the present invention is injected into a blood vessel to replace blood at an intravascular portion to be inspected therewith in making an in-vivo intravascular inspection. The blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance, unharmful for the living body, which is added to the aqueous medium to impart a gelling property to the blood replacing liquid. The blood replacing liquid has a viscosity of not more than 3 mPa·s when the blood replacing liquid is injected into the blood vessel.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 13, 2019
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Koji Nakamura, Isao Mori, Masanori Tokida
  • Publication number: 20150139938
    Abstract: The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 21, 2015
    Applicant: Ohio State Innovation Foundation
    Inventors: Chandan Sen, Cameron Rink, Sashwati Roy, Greg Christoforidis
  • Publication number: 20150140121
    Abstract: Compositions and methods for modifying the composition of tight junction complexes and/or improving epithelial barrier function are disclosed.
    Type: Application
    Filed: June 10, 2013
    Publication date: May 21, 2015
    Inventors: James M. Mullin, Jonathan M. Raines
  • Patent number: 8992999
    Abstract: A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: March 31, 2015
    Assignee: Alltech, Inc.
    Inventors: Cepta Duffy, Aidan Joseph Connolly
  • Patent number: 8987244
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the h
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 24, 2015
    Assignee: PhilERA New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Publication number: 20150056298
    Abstract: According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventors: Bobak Robert Azamian, Scott Bradley Vafai
  • Publication number: 20150056297
    Abstract: A dietary supplement in capsule or tablet form includes a source of zinc in an amount equivalent to 6 mg to 40 mg of zinc chloride; optionally a source of chromium in an amount equivalent to 100 micrograms to 1000 micrograms of chromium picolinate; optionally from 4 micrograms to 100 micrograms of Vitamin B12; optionally an extract or powdered form of American Ginseng in an amount that provides from 20 mg to 200 mg of ginsenoside(s), or 20 mg to 200 mg of isolated or synthesized ginsenoside(s); optionally an oil, extract or powdered form of cinnamon bark in an amount that provides 1000 mg to 5000 mg of methylhydroxychalcone polymer; optionally 2 mg to 50 mg lutein; and optionally green tea extract in an amount that provides from 200 mg to 4000 mg of epigallocatechin gallate or 200 mg to 4000 mg of isolated or synthesized epigallocatechin gallate.
    Type: Application
    Filed: August 18, 2014
    Publication date: February 26, 2015
    Inventor: Charles H. Liu
  • Patent number: 8962696
    Abstract: The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2, 6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsion preparation. In a preferred two (2) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; and liquid propofol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 4% by weight of propofol to the volume of the microemulsion. In a four (4) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; liquid propofol; a water-immiscible solvent; and ethanol.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: February 24, 2015
    Assignee: Medos, Inc.
    Inventors: Steven B. Harris, Nick J. Huang
  • Publication number: 20150050261
    Abstract: The present invention relates to dietary and nutritional supplements comprising various vitamins, minerals and nutrients, including an omega-3 fatty acid of plant-based origin and a folate derivative.
    Type: Application
    Filed: August 15, 2014
    Publication date: February 19, 2015
    Inventors: Chris G. Evenstad, Kelly M. Heimerl, Mike J. McBride, Ronnie Ortiz, Carrol J. Rhead, Sami Yusuf, Michelle B. Zachman
  • Publication number: 20150030698
    Abstract: An oral product that includes an amino acid nitric oxide precursor and a compound capable of providing zinc ions. The product can be formulated as a powder and mixed with a liquid in preparation for consumption by a person. The powdered formulation may be mixed with water followed by a brief but necessary allotment of time for the powdered formulation to completely react in the water. The resulting beverage may then be consumed by a person or user to facilitate production of nitric oxide and creatine-phosphate that is usable by the person, especially to help recover and rejuvenate the person after physical exertion and reduce or relieve muscle soreness.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 29, 2015
    Inventor: R. Charles Thompson
  • Publication number: 20150024067
    Abstract: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins and zinc (provided as Zn (II) EDTA alkali metal salt) mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is totally non-toxic in chemical nature and non-offensive in odor to others, so it can be used anywhere and at any time and can be swallowed after use.
    Type: Application
    Filed: October 7, 2013
    Publication date: January 22, 2015
    Inventors: Plato Chun-Chih Lee, Arthur Joseph Dietrich
  • Patent number: 8916150
    Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: December 23, 2014
    Assignee: CNSS IP Holdings, Inc.
    Inventor: Charles N. S. Soparkar
  • Publication number: 20140342018
    Abstract: The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated using in vitro and in vivo estimations. The dosage for promoting bone health and alleviation of osteoporosis is about a quarter to a third of the conventional dose.
    Type: Application
    Filed: April 1, 2014
    Publication date: November 20, 2014
    Applicant: Sinoveda Canada Inc.
    Inventor: Yun Kau TAM
  • Patent number: 8883221
    Abstract: Micronutrient combination product, wherein the micronutrient combination product comprises zeaxanthin, lutein, zinc and copper.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: November 11, 2014
    Assignee: Bausch & Lomb Incorporated
    Inventors: Guenter Bellmann, Gudrun Claus-Herz
  • Publication number: 20140308369
    Abstract: An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.
    Type: Application
    Filed: October 25, 2012
    Publication date: October 16, 2014
    Applicant: INTERNATIONAL NUTRITION RESEARCH COMPANY
    Inventor: Claude Vincent
  • Publication number: 20140302169
    Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventor: Richard Roberts
  • Patent number: 8840933
    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: September 23, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C Marx
  • Publication number: 20140255512
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Franco GAETANI, Ashraf VIRMANI
  • Publication number: 20140242161
    Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 28, 2014
    Inventors: Giorgio ZOPPETTI, Maurizio MARCHIORRI
  • Publication number: 20140227371
    Abstract: The present invention relates to edible compositions for the maintenance of normal liver function comprising zinc, 1-deoxynojirimycinand ?-lipoic acid.
    Type: Application
    Filed: May 31, 2012
    Publication date: August 14, 2014
    Inventors: Alan David Heath, Dawn Jennae Mazzatti, Charlotte Mary Walden
  • Publication number: 20140212508
    Abstract: A Copper/Zinc superoxide dismutase (Cu/Zn SOD) composition comprising a therapeutically effective amount of ionic mineral(s) in a ligand complex and a pharmaceutically acceptable carrier for the neutralization of superoxide produced trauma and/or stress-related conditions including, but not limited to, conditions such as myotrophic lateral sclerosis (ALS). The composition may also include other supporting adjutants such as bioavailable magnesium, manganese, selenium and other minerals that can support the nervous system and other vitamins and glutathione and other nutrients. Botanical extracts, urea, other supplements helpful for protection and re-enforcement of the immune system are discussed.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 31, 2014
    Inventor: John Wayne Kennedy
  • Publication number: 20140199414
    Abstract: The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 17, 2014
    Applicant: Neptune Technologies & Bioressources Inc.
    Inventor: Tina Sampalis
  • Patent number: 8778311
    Abstract: The present invention relates to an oral composition comprising, in an orally acceptable carrier, from about 0.1% to about 5% zinc oxide; and from about 0.1% to about 5% of a source of carbonate ions selected from alkali metal and ammonium carbonates and bicarbonates. The molar ratio of carbonate ion to zinc ion is from about 0.05:1 to about 1:1. The composition has good antiplaque efficacy and taste. Preferred compositions are toothpastes.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: July 15, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Meinrad Regner, Maurice Joseph Prendergast, Owen Thurlby
  • Patent number: 8778410
    Abstract: The present invention provides an oral or enteral composition incorporating not only BCAA but other nutrients to be conducive to comprehensive recovery from fatigue, and improvement in total physical condition. The oral or enteral composition is formulated as a composite of a branched-chain amino acid, coenzyme Q10, L-carnitine, a citric acid, and zinc.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 15, 2014
    Assignees: Earnest Medicine Co., Ltd., Otsuka Pharmaceutical Factory, Inc.
    Inventors: Takashi Higashiguchi, Takako Hatakeyama
  • Publication number: 20140161890
    Abstract: A magnetic oxide-quantum dot nanocomposite has at least one magnetic oxide nanoparticle coated with a silica (SiO2) shell and terminated with at least one thiol group (—SH) and at least one CdSe/ZnS quantum dot linked with the at least one SiO2-coated magnetic oxide nanoparticle via the at least one thiol group. The at least one magnetic oxide nanoparticle can be an iron oxide (Fe3O4) nanoparticle. A method of cancer treatment using the magnetic oxide-quantum dot nanocomposites, includes the steps of delivering a plurality of nmagnetic oxide-quantum dot nanocomposites to a cancer cell, and subjecting the cancer cell with the plurality of magnetic oxide-quantum dot nanocomposites to a radio frequency induction for a period of time effective to cause the cancer cell to die.
    Type: Application
    Filed: February 17, 2014
    Publication date: June 12, 2014
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Alexandru S. Biris, Yang Xu, Daoyuan Wang
  • Publication number: 20140161907
    Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Inventors: John A. Giordano, Charles J. Balzer
  • Publication number: 20140154339
    Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. This method is also directed to treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.
    Type: Application
    Filed: May 22, 2013
    Publication date: June 5, 2014
    Inventors: John P. Geibel, Phillipp Kirchhoff
  • Publication number: 20140147515
    Abstract: A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.
    Type: Application
    Filed: July 21, 2004
    Publication date: May 29, 2014
    Applicant: Alltech, Inc.
    Inventors: Cepta Duffy, Aidan Joseph Connolly
  • Publication number: 20140113004
    Abstract: Methods of inhibiting Barrett's esophagus and/or adenocarcinoma in a subject are provided. In a particular embodiment, the method comprises administering at least one composition comprising at least one zinc compound and at least one pharmaceutically acceptable carrier to the esophagus of the subject. The zinc may be a pharmaceutically acceptable salt of zinc, such as zinc gluconate. The zinc may be administered, for example, orally, topically, or by an implantable medical device. In a particular embodiment, the methods further comprise administering at least one analgesic, anesthetic, or other therapeutic agent or therapy for the treatment of Barrett's esophagus. The method may further comprise monitoring the progression of Barrett's esophagus in the subject.
    Type: Application
    Filed: May 7, 2012
    Publication date: April 24, 2014
    Applicants: Monk Street Partners LLC, Lankenau Institute for Medical Research
    Inventors: James M. Mullin, Jonathan Raines
  • Patent number: 8673362
    Abstract: The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 18, 2014
    Assignee: Immunopath Profile, Inc.
    Inventor: Leonard S. Girsh
  • Patent number: 8658218
    Abstract: A composition for treating damaged tissue and promoting healthy tissue growth, healing and tissue regeneration, wherein the composition comprises an extracellular matrix compound, a surface-active lipid, one or more enantiomericaily pure L-amino acids or glycine, a hydrophilic surfactant with a high HLB, as well as vitamins, minerals or trace elements. Not only does it maintain good health, but the components are non-intrusive, bio-safe, non-coalescent and can mimic normally occurring stem-cells within a body. When applied to diseased tissues, the subject compositions can stimulate, facilitate, and accelerate protein synthesis for the regeneration of diseased organs and tissues. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: February 25, 2014
    Assignee: Immunopath Profile, Inc.
    Inventor: Leonard S. Girsh
  • Patent number: 8652495
    Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an oral care composition comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and at least one amino acid capable of chelating the metal oxide. The composition may comprise a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 18, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Venda Porter, Andre Morgan, Michael Prencipe
  • Publication number: 20140044685
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Patent number: 8641776
    Abstract: This invention relates in one aspect to the treatment of a vascular vessel with a biomaterial. The biomaterial can be a remodelable material that strengthens and/or supports the vessel walls. Additionally the biomaterial can include a variety of naturally occurring or added bioactive agents and/or viable cellular populations.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: February 4, 2014
    Assignees: Cook Biotech Incorporated, Cook Medical Technologies LLC
    Inventors: Brian C. Case, Michael C. Hiles, Jacob A. Flagle, F. Joseph Obermiller, Umesh H. Patel
  • Publication number: 20140030241
    Abstract: Nutritional compositions having dietary nucleotides, ?-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided.
    Type: Application
    Filed: March 15, 2012
    Publication date: January 30, 2014
    Applicant: NESTEC S.A.
    Inventor: Norman Alan Greenberg
  • Publication number: 20140017338
    Abstract: A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with a G-protein coupled to receptor located in the cilia to moderate (enhance or reduce) sensitivity or ability to smell particular odorants. In accordance with an embodiment of the invention, the composition includes one or more odorants.
    Type: Application
    Filed: September 17, 2013
    Publication date: January 16, 2014
    Applicant: Auburn University
    Inventors: Vitaly J. Vodyanoy, Nilmini Viswaprakash, Ludmila Petrovna Globa, Edward E. Morrison
  • Publication number: 20140017337
    Abstract: Therapeutic methods includes several stages, including a modified fasting and low calorie stages, with low impact, moderate exercise, a sliming stage, and a maintenance stage. Nutritional therapeutics are also consumed during each phase, which support a plurality of metabolic and physiological functions.
    Type: Application
    Filed: July 11, 2012
    Publication date: January 16, 2014
    Inventor: Paul Amoruso
  • Publication number: 20130344167
    Abstract: The present invention relates to a galenic composition suitable for administration to a non-human animal, including at least the following three components: one or more active principles; an agent for accelerating delitescence; an agent for delaying delitescence, wherein the agent for accelerating delitescence an the agent for delaying delitescence are integrated in the composition so as to form a matrix with the controlled release of the active principle(s). The invention also relates to the uses of said compositions, as well as to a method for measuring the in vitro delitescence thereof.
    Type: Application
    Filed: November 27, 2011
    Publication date: December 26, 2013
    Applicant: VETALIS SARL
    Inventors: Laurent Chery, Jean-Pierre Wajda-Dubos
  • Publication number: 20130330411
    Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].
    Type: Application
    Filed: July 15, 2013
    Publication date: December 12, 2013
    Inventor: Ivan Coulter
  • Publication number: 20130316017
    Abstract: Provided is a composition that is useful for treating acne, and which has been found to reduce and/or eliminate acne outbreaks or reduce the severity thereof. The composition includes mangosteen and curcumin. At least a portion of the mangosteen and curcumin can be provided in the form of extracts thereof. The composition can optionally include other components such as guggul, guggul extracts, thyme, thyme extracts, piperine, vitamin B5, vitamin B6, zinc, beta glucans, and green tea extracts. The composition can be provided as an oral administration unit such as a pill or capsule. Also provided is a method of treating acne by ingesting an effective amount of the composition described herein.
    Type: Application
    Filed: May 24, 2013
    Publication date: November 28, 2013
    Inventor: Michael Hynes
  • Patent number: 8591884
    Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: November 26, 2013
    Assignee: CNSS IP Holdings, Inc
    Inventor: Charles N. S. Soparkar
  • Patent number: 8580316
    Abstract: A nutritional or pharmaceutical composition comprising fat, protein, carbohydrate, whey and casein is provided. The composition has a weight ratio of casein to whey between 1:1 to 1:2.4 and comprises: a) at least 3 grams arginine per 100 grams protein; b) at least 10 wt. % linoleic acid based on total fatty acids; c) at least 1 wt. % alpha linolenic acid based on total fatty acids; d) at least one long chain-polyunsaturated fatty acid in an amount exceeding 0.1 wt. % based on total fatty acids selected from docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid; e) 5 to 25 wt. % of at least one polyunsaturated fatty acid based on total fatty acids; and 2 to 12 grams indigestible oligosaccharides having a degree of polymerisation of 2 to 100 per 100 gram dry weight of the composition. Methods of treatment by administering the composition are also provided.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: November 12, 2013
    Assignee: N. V. Nutricia
    Inventors: Günther Boehm, Christopher Beermann, Bernd Stahl, Laura M'Rabet, Johan Garssen
  • Publication number: 20130295179
    Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.
    Type: Application
    Filed: April 12, 2013
    Publication date: November 7, 2013
    Inventors: Christian TERREAUX, Eleonora HOMBERGER, Burkhard KRIWET, Eduardo BARRAGAN PEREZ
  • Patent number: 8569272
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Robert T. Lyons, James N. Chang, John T. Trogden, Scott M. Whitcup
  • Patent number: 8563538
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: October 22, 2013
    Assignee: Philera New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Patent number: 8562860
    Abstract: A method for activating hydrogen molecules dissolved in water and stabilizing the concentration of the hydrogen molecules is provided. The method for activating and stabilizing hydrogen molecules dissolved in water is characterized by allowing hydrogen ions to coexist with the hydrogen molecules.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: October 22, 2013
    Assignee: Spring Co., Ltd.
    Inventor: Osao Sumita
  • Patent number: 8545810
    Abstract: Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: October 1, 2013
    Inventor: Jef Gazley
  • Publication number: 20130243845
    Abstract: The subject invention relates to a chocolate or compound chocolate product comprising added functional ingredients including vitamin C, vitamin E, zinc, copper and, optionally, a xanthophyll. The invention further concerns the production of such chocolates and compound chocolate products, their assembly in kit formats and the use of these products for the therapy of diseases of the eye, in particular macular degeneration and cataract formation, or for the maintenance and support of general eye health.
    Type: Application
    Filed: April 18, 2013
    Publication date: September 19, 2013
    Applicant: Ophthalmopharma AG
    Inventors: Mordechai GERON, Samir DE CHADAREVIAN
  • Publication number: 20130243720
    Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.
    Type: Application
    Filed: June 27, 2012
    Publication date: September 19, 2013
    Inventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley